<DOC>
	<DOCNO>NCT00238173</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , etoposide phosphate , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Mannitol may help chemotherapy work well make easy drug get tumor . Chemoprotective drug , acetylcysteine sodium thiosulfate , may protect normal cell side effect chemotherapy . Giving acetylcysteine together mannitol , combination chemotherapy , sodium thiosulfate may effective treatment malignant brain tumor . PURPOSE : This phase I trial study side effect best dose acetylcysteine give together mannitol , combination chemotherapy , sodium thiosulfate treat child malignant brain tumor .</brief_summary>
	<brief_title>Acetylcysteine , Mannitol , Combination Chemotherapy , Sodium Thiosulfate Treating Children With Malignant Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity maximum tolerate dose acetylcysteine give combination blood-brain barrier disruption treatment mannitol , combination chemotherapy comprise cyclophosphamide , etoposide phosphate , carboplatin , delay high-dose sodium thiosulfate pediatric patient malignant brain tumor . Secondary - Determine blood/bone marrow toxicity regimen patient . - Determine tumor response patient treat regimen . OUTLINE : This dose-escalation study acetylcysteine . Patients receive acetylcysteine IV 30-60 minute follow , least 15 minute later , x-ray-guided femoral artery catheterization general anesthesia day 1 2 . After placement catheter , patient receive cyclophosphamide IV 10 minute , etoposide phosphate IV 10 minute , mannitol intra-arterially ( IA ) 30 second , carboplatin IA 10 minute also day 1 2 . Patients receive high-dose sodium thiosulfate IV 15 minute 4 hour completion carboplatin . Some patient may receive second dose sodium thiosulfate 8 hour completion carboplatin . Beginning 48 hour last dose chemotherapy day 2 , patient receive filgrastim ( G-CSF ) subcutaneously daily 7-10 day blood count recover . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos acetylcysteine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 3 patient treated MTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm brain tumor , include follow : Brain stem glioma Primitive neuroectodermal tumor CNS germ cell tumor Malignant glioma Diagnosis base following : CTassisted stereotactic biopsy Open biopsy Surgical resection Cerebrospinal fluid cytology Elevated tumor marker Unequivocal radiographic change ( patient brain stem glioma optic glioma ) All tumor type , except brain stem glioma , must recurrent No radiographic sign intracranial herniation and/or spinal cord block PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy At least 90 day Hematopoietic WBC ≥ 2,500/mm^3 Absolute granulocyte count ≥ 1,200/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic SGOT SGPT &lt; 2.5 time upper limit normal Bilirubin &lt; 2.0 mg/dL Renal Creatinine &lt; 1.8 mg/dL Pulmonary No history clinically significant reactive airway disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant risk general anesthesia No uncontrolled , clinically significant , confound medical condition within past 30 day No contraindication study drug PRIOR CONCURRENT THERAPY : Chemotherapy At least 28 day since prior systemic chemotherapy Radiotherapy At least 3 month since prior total spine radiotherapy At least 14 day since prior cranial radiotherapy Prior systemic radiotherapy allow Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>bone marrow suppression</keyword>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood central nervous system choriocarcinoma</keyword>
	<keyword>childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood central nervous system germinoma</keyword>
	<keyword>childhood central nervous system mixed germ cell tumor</keyword>
	<keyword>childhood central nervous system teratoma</keyword>
	<keyword>childhood central nervous system yolk sac tumor</keyword>
	<keyword>recurrent childhood central nervous system embryonal tumor</keyword>
</DOC>